Arena Pharmaceuticals Inc ARNA:NASDAQ

Last Price$92.41Cboe Real-Time Last Sale as of 12:26PM ET 1/18/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.24(0.26%)
Bid (Size)$92.41 (600)
Ask (Size)$92.48 (500)
Day Low / High$92.26 - 92.84
Volume591.2 K
 

View Biotechnology IndustryPeer Comparison as of 01/18/2022

 

Arena Pharmaceuticals Inc ( NASDAQ )

Price: $92.41
Change: -0.24 (0.26%)
Volume: 591.2 K
12:26PM ET 1/18/2022
 
 

Exelixis Inc ( NASDAQ )

Price: $17.70
Change: -0.42 (2.32%)
Volume: 647.1 K
12:26PM ET 1/18/2022
 
 

Arrowhead Pharmaceuticals Inc ( NASDAQ )

Price: $55.05
Change: -2.76 (4.77%)
Volume: 150.5 K
12:16PM ET 1/18/2022
 
 

Sarepta Therapeutics Inc ( NASDAQ )

Price: $66.40
Change: -4.70 (6.61%)
Volume: 600.6 K
12:25PM ET 1/18/2022
 
 

Natera Inc ( NASDAQ )

Price: $64.52
Change: -2.85 (4.23%)
Volume: 834.3 K
12:25PM ET 1/18/2022
 

Read more news Recent News

Cantor Fitzgerald Downgrades Arena Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $100 From $93
5:06AM ET 12/21/2021 MT Newswires

Arena Pharmaceuticals (ARNA) has an average rating of hold and price targets ranging from $80 to $120, according to analysts polled by Capital IQ. (MT...

Arena's PT Hiked to $100 by RBC in Line With Pfizer's Proposed Bid; Downgraded to Sector Perform as no Deal Hurdles Seen
3:37PM ET 12/14/2021 MT Newswires

Arena Pharmaceuticals' (ARNA) price target has been raised to $100 from $76 by RBC Capital on Tuesday in line with Pfizer's (PFE) proposed acquisition...

Citigroup Downgrades Arena Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $100 From $101
10:03AM ET 12/14/2021 MT Newswires

Arena Pharmaceuticals (ARNA) has an average outperform rating and a price target range of $80 to $120, according to analysts polled by Capital IQ. (MT...

--Needham Downgrades Arena Pharmaceuticals to Hold From Buy, Drops $80 Price Target
9:15AM ET 12/14/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Arena (ARNA) Stock Up in 6 Months on PFE Merger Deal & Pipeline
10:24AM ET 1/18/2022 Zacks

Arena Pharmaceuticals' (ARNA) potential acquisition by Pfizer to enable it to advance the...

Zynga Trades At A 10% Discount To Take-Two's Purchase Offer; Expect That Gap To Partially Close Soon
11:00AM ET 1/11/2022 Seeking Alpha

Merger Arbitrage Mondays - The Bidding War For R. R. Donnelley Continues
11:59PM ET 1/03/2022 Seeking Alpha

Merger Arbitrage Mondays: Oracle Enters Healthcare Tech With The Cerner Acquisition
11:43AM ET 12/27/2021 Seeking Alpha

Company Profile

Business DescriptionArena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA. View company web site for more details
Address6154 Nancy Ridge Drive
San Diego, California 92121-9604
Phone+1.858.453.7200
Number of Employees194
Recent SEC Filing01/07/2022DEFA14A
President, Chief Executive Officer & DirectorAmit Dilip Munshi
Chief Financial Officer & Executive Vice PresidentLaurie D. Stelzer
Chief Medical Officer & SVP-Clinical DevelopmentPaul D. Streck
Executive Vice President-Research & DevelopmentDouglas J. Manion

Company Highlights

Price Open$92.60
Previous Close$92.65
52 Week Range$45.50 - 94.23
Market Capitalization$5.7 B
Shares Outstanding61.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/22/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$9.05
Beta vs. S&P 500N/A
Revenue$18.0 M
Net Profit Margin-1,575,635.14%
Return on Equity-59.21%

Analyst Ratings as of 12/17/2021

Buy
3
Overweight
0
Hold
10
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset